Sign In
Free Newsletter
NJ Assembly advances PBM reform bill to cut drug costs
The New Jersey General Assembly advanced a measure that aims to lower prescription drug costs, increase transparency and regulate PBMs in New Jersey's healthcare system.
Trump 100% pharma tariffs raise concerns for New Jersey life sciences (updated)
The president's levies on imported drugs and ingredients raise concerns for New Jersey’s life sciences sector, with risks to costs and innovation.
On the scene: Sherrill, Caldwell keynote industry events
NJBIZ was on location at two business gatherings Friday: one examining the state's life sciences industry and another highlighting the 2026 World Cup.
Business groups react to Sherrill’s $60.7B NJ budget, mixed reviews (updated)
Business groups and policy advocates are weighing in on Gov. Mikie Sherrill’s $60.7 billion spending plan, applauding cuts and reforms while noting tax concerns.
NJBIZ Conversations: Healthcare Institute of New Jersey CEO Chrissy Buteas
The Healthcare Institute of New Jersey CEO discusses the challenges facing a crucial segment of the state's economy.
US, UK finalize pharma pricing deal to boost innovation
The agreement raises United Kingdom payments for medicines, easing cost pressures domestically as well as strengthening United States life sciences investment.
On the scene: 2025 NJBIZ Women’s Leadership Summit
The second annual event gathered industry leaders in Somerset for a day of inspiration, featuring keynote Chrissy Buteas, panel discussions, networking and a Community FoodBank drive.
Novo Nordisk, Eli Lilly cut GLP-1 drug costs under Medicare
The deals with the Trump administration will lower prices for weight loss and diabetes medications to make them more affordable for patients.
Trump drug tariff draws backlash from NJ pharma industry
New Jersey’s pharmaceutical leaders warn the president's proposed levy could raise costs, disrupt supply chains and hurt patient access.
Health care leader to keynote NJBIZ Women’s Leadership Summit
Taking place Nov. 12 in Somerset, the second annual event will offer a powerhouse morning focused on career development, personal growth, leadership and networking.
Trump drug pricing order draws NJ pharma industry backlash
Local industry leaders say the attempt to lower costs could harm innovation, threaten jobs and import failed foreign pricing models to U.S. markets.
OPINION: Beware of new regs
The president and CEO of the HealthCare Institute of New Jersey says "recent policy changes by the Federal Trade Commission and Department of Justice could jeopardize our state’s status as a health care leader."
